SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > All Ingredients News

Dispatches from BPI 2015

Pfizer's vetting process sorts the strategic CMOs from the casual flings

15-Apr-2015 - Looking for a full-on partnership with Pfizer or a no-strings-attached manufacturing deal? Either way prepare for a tough screening process and don't be located too far from an airport.

API quality concerns prompt fines and drug recall orders in Taiwan

13-Apr-2015 - Thirteen Taiwanese drugmakers have been fined and ordered to recall products by regulators concerned the APIs they contain are food rather than pharma grade.

Predicting oral bioavailability is better with AI says PharmaInformatic

09-Apr-2015 - Artificial intelligence can aid lead optimisation according to the German firm behind a new structure-based drug oral bioavailability prediction technology. 

IPEC calls for excipient GMP standard implementation plans to be in place by Q4

07-Apr-2015 - IPEC-Americas (International Pharmaceutical Excipient Council) stopped short of recommending a specific date for implementation of a new GMP standard for excipient manufacturers, but the group is calling on manufacturers to have an implementation plan in place by the end of Q3 of this year.

Biocon's Syngene in silent period but lays plans for API plant in India

07-Apr-2015 - Biocon subsidiary Syngene says it intends to build a commercial manufacturing plant for APIs and intermediates in Mangalore, India.

What's in a name? The results of our banned sex supplement quiz

01-Apr-2015 -   Learn more about pharmaceutical fakes at in-Pharmatechnologist.com's Anti-Counterfeiting Forum on April 16, 2016.

Onyx Scientific expands API facility on Phase I/II demand

01-Apr-2015 - A rise in demand for small scale APIs has driven Onyx Scientific to expand its GMP operations in North-East England.

Register now for our free online event

The latest developments in drug excipients: Exclusive online event

25-Mar-2015 - Want the latest market information, and scientific insights in the pharmaceutical excipients market? Then join us at our free online event, Excipients Innovations 2015.

AstraZeneca teams with Harvard to make human beta cells for drug screening

25-Mar-2015 - Sourcing human beta cells may soon no longer be a challenge for AstraZeneca diabetes researchers thanks to a new partnership with stem cell scientists at Harvard University.

update

Novasep joins Lonza as Mydicar API producer in deal with Celladon

25-Mar-2015 - Novasep and Lonza will both make the API for Celladon's heart attack therapy, Mydicar.

Growth with aid of Grey: Elderly folks to drive excipients sector, study

24-Mar-2015 - Demand for pensioner friendly pills will be an important growth driver for the drug excipients sector according to new analysis.

Lilly inks $450m oncology drug development collaboration in China

20-Mar-2015 - Eli Lilly and China biotech Innovent Biologics will collaborate to develop at least three cancer treatments over the next decade. 

NSF publishes first US standard for pharmaceutical excipients

17-Mar-2015 - NSF International has published a new standard and developed an auditing program that can help pharma companies verify regulatory compliance and strengthen safety and quality across their excipient supply chain.

News in brief

Porton Fine Chem buys fellow China intermediates firm Dongbang

16-Mar-2015 - Porton Fine Chemicals will buy fellow China-based firm Jiangxi Dongbang Pharmaceutical adding intermediates for antivirals and cholesterol busters to its portfolio.

QUIZ

'Black Mamba' or 'OMG': which (fake) sexual enhancement pill has the best name?

12-Mar-2015 - The FDA has tested hundreds of creatively named bogus supplements and found they contain hidden APIs. Take in-Pharmatechnologist.com's quiz and tell us which name is your favourite.

AMRI sets sights on acquiring Indian API manufacturer, CEO says

11-Mar-2015 - Following its three acquisitions over the last year, AMRI is now looking to extend its footprint into India further with the acquisition of a FDA-approved API site, William Marth, president and CEO of AMRI, told attendees at the Barclays Global Healthcare Conference on Wednesday.

Johnson Matthey builds HPAPI site in Scotland

11-Mar-2015 - API- and catalyst-maker Johnson Matthey has built high containment facilities for potent products at its site in Edinburgh, Scotland.

J&J pleads guilty, pays $25m over manufacturing adulterated infants’, children’s OTC medicines

10-Mar-2015 - J&J unit McNeil-PPC has admitted breaking US law by selling contaminated liquid medications, including Infants’ Tylenol and Children’s Motrin, deemed adulterated under the federal Food, Drug and Cosmetic Act (FDCA).

Pfizer's plant in Little Island to stay open after higher Lipitor demand

10-Mar-2015 - Pfizer will continue to make Lipitor at its plant in Little Island, Ireland after an increase in demand for the cholesterol buster.

APIs in banned sex supplements sold openly online says regulator

09-Mar-2015 - Tests show Viagra and Cialis APIs present in over 100 brands of bogus ‘sexual enhancement’ pill.

Patheon: Irix deal about US and Canadian customer demand for local APIs; all staff to be retained

05-Mar-2015 - Irix Pharmaceuticals will cater for North American customers’ desire for local supply according to Patheon, which says it plans to retain the API firm’s 180 staff.

Hundreds of API suppliers with plants in new Indian state Telangana need to update EDQM

04-Mar-2015 - As many as 450 API and intermediate suppliers in India's newest State - Telangana – need to log their changed addresses with the EDQM before August.

Patheon has bought hard-to-make API specialist Irix Pharmaceuticals

04-Mar-2015 - Patheon has bought hard-to-manufacture active pharmaceutical ingredient (API) specialist, Irix Pharmaceuticals.

US defence cuts an opportunity for generics firm KVK Tech

04-Mar-2015 - US fighter jet firm Lockheed Martin has agreed to sell a satellite production plant in Newtown, Pennsylvania to drugmaker KVK-Tech.

AZ spins out antibiotics R&D biz to focus on key pipelines

04-Mar-2015 - AstraZeneca will spend $40m spinning out its antibiotics R&D business into a separate subsidiary, saying the move will let it focus on its core disease areas.

Spotlight

Distributing donated drugs a major challenge says UK neglected diseases group

Distributing donated drugs a major challenge says UK neglected diseases group

More drugs for tropical diseases have been donated since the London declaration of 2012, but getting them...

Novasep to make API for Celladon's heart attack gene therapy
update

Novasep joins Lonza as Mydicar API producer in deal with Celladon

Novasep and Lonza will both make the API for Celladon's heart attack therapy, Mydicar.

Lethal injection drug shortage brings return of firing squad in Utah

Lethal injection drug shortage brings return of firing squad in Utah

Utah will allow execution by firing squad as European pharmaceutical companies refuse to provide drugs for lethal...

Growing elderly population to drive drug excipients sector, study

Growth with aid of Grey: Elderly folks to drive excipients sector, study

Demand for pensioner friendly pills will be an important growth driver for the drug excipients sector according...

WHO calls for proactive strategies to combat falsified, substandard medicines

WHO calls for proactive strategies to combat falsified, substandard medicines

The WHO’s latest report on substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) medical products has the organization divvying up certain responsibilities for...

US diabetics pay most for drugs, but world’s poorest bear the biggest economic burden

US diabetics pay most for drugs, but world’s poorest bear the biggest economic burden

Further evidence US diabetics pay more for drugs than sufferers in comparable countries has emerged this month...

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...